Groenendijk Alissa, Spreafico Filippo, de Krijger Ronald R, Drost Jarno, Brok Jesper, Perotti Daniela, van Tinteren Harm, Venkatramani Rajkumar, Godziński Jan, Rübe Christian, Geller James I, Graf Norbert, van den Heuvel-Eibrink Marry M, Mavinkurve-Groothuis Annelies M C
Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands.
Department of Medical Oncology and Hematology, Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
Cancers (Basel). 2021 Jun 23;13(13):3142. doi: 10.3390/cancers13133142.
In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%. However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors currently used for risk stratification (advanced stage, high risk histology, and combined loss of heterozygosity at 1p and 16q in chemotherapy-naïve WTs) are present in only one third of these cases, and the significance of these factors is prone to change with advancing knowledge and improved treatment regimens. Therefore, we present a comprehensive, updated overview of the published prognostic variables for WT recurrence, ranging from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. Improved first-line treatment regimens based on clinicopathological characteristics and advancing knowledge on copy number variations unveil the importance of further investigating the significance of biological markers for WT recurrence in international collaborations.
在高收入国家,肾母细胞瘤(WT)患儿的总体生存率约为90%。然而,总体而言,15%的患者会出现肿瘤复发。目前用于风险分层的不良预后因素(晚期、高危组织学以及初治WT中1p和16q杂合性联合缺失)仅存在于三分之一的此类病例中,并且随着知识的进步和治疗方案的改进,这些因素的意义易于改变。因此,我们提供了一份全面、更新的关于WT复发的已发表预后变量概述,范围涵盖从患者、肿瘤和治疗相关特征到地理和社会经济因素。基于临床病理特征的改良一线治疗方案以及对拷贝数变异认识的不断深入,揭示了在国际合作中进一步研究WT复发生物学标志物意义的重要性。